MedPath

Predicting Toxicity in Elderly Patients With Head and Neck Cancer

Recruiting
Conditions
Head and Neck Cancer
Registration Number
NCT06344208
Lead Sponsor
European Institute of Oncology
Brief Summary

Predicting toxicity in elderly patients with head and neck cancer:

validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.

Detailed Description

We aim to analyze clinical and biochemical variables to prospectively create and validate an independ-ent predictive score to identify the probability of G3-5 toxicity in HNC elderly patients candidated to a curative treatment with radiation treatment +/- systemic treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
3
Inclusion Criteria
  • Patients aged ≥ 70 years
  • Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab)
  • Evaluable disease accordingly to RECIST criteria 1.1
  • Willing of sign a written informed consent
  • Adequate organ function
Exclusion Criteria

Patient with cancer in other sites than HN < than 2 years except for prostate cancer cT1-2, Gleason 3+3, NIMBC, initial Non Melanoma Skin Cancer, in situ cervical cancer)

  • PS ECOG 3-4
  • Patients who received systemic treatments in the past for other primary tumors

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Predicting toxicity in elderly patients with head and neck cancer2 years

validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

European Institute of Oncology

🇮🇹

Milan, Italy

© Copyright 2025. All Rights Reserved by MedPath